Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects

References

• Vasan RS, Beiser A, Seshadri S et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA287(8), 1003–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension35(2), 539–543 (2000).
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360(9349), 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Woodward M, Neal B et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur. Heart J.29(21), 2669–2680 (2008).
   PubMed Web of Science ®Google Scholar
• Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet356(9246), 1955–1964 (2000).
   PubMed Web of Science ®Google Scholar
• The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet1(8181), 1261–1267 (1980).
   PubMed Web of Science ®Google Scholar
• Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Prepared for the Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Ann. NY. Acad. Sci.304, 267–292 (1978).
   PubMedGoogle Scholar
• MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br. Med. J. (Clin. Res. Ed.)291(6488), 97–104 (1985).
   PubMed Web of Science ®Google Scholar
• The effect of treatment on mortality in “mild” hypertension: results of the hypertension detection and follow-up program. N. Engl. J. Med.307(16), 976–980 (1982).
   PubMed Web of Science ®Google Scholar
• Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA213(7), 1143–1152 (1970).
   PubMed Web of Science ®Google Scholar
• Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. JAMA247(5), 633–638 (1982).
   PubMed Web of Science ®Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA248(12), 1465–1477 (1982).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet338(8778), 1281–1285 (1991).
   PubMed Web of Science ®Google Scholar
• Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ304(6824), 405–412 (1992).
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA265(24), 3255–3264 (1991).
   PubMed Web of Science ®Google Scholar
• Rosei EA, Dal Palu C, Leonetti G et al.; VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J. Hypertens.15(11), 1337–1344 (1997).
   PubMed Web of Science ®Google Scholar
• Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet356(9227), 366–372 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet356(9227), 359–365 (2000).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359(9311), 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288(23), 2981–2997 (2002).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet353(9153), 611–616 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet354(9192), 1751–1756 (1999).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet350(9080), 757–764 (1997).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA290(21), 2805–2816 (2003).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet366(9489), 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359(23), 2417–2428 (2008).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363(9426), 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ336(7653), 1121–1123 (2008).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Williams M, Dworkin L et al.; National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am. J. Kidney Dis.36(3), 646–661 (2000).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42(6), 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J.28(12), 1462–1536 (2007).
   PubMed Web of Science ®Google Scholar
• Psaty BMJ, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA289(19), 2534–2544 (2003).
   PubMed Web of Science ®Google Scholar
• Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet362(9395), 1527–1535 (2003).
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation115(21), 2761–2788 (2007).
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L, Berglund G, Elmfeldt D et al. β-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J. Hypertens.5(5), 561–572 (1987).
   PubMed Web of Science ®Google Scholar
• Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ317(7160), 713–720 (1998).
   PubMed Web of Science ®Google Scholar
• Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. The Captopril Prevention Project (CAPP) Study Group. Curr. Hypertens. Rep.1(6), 466–467 (1999).
   PubMedGoogle Scholar
• The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med.140(10), 1280–1285 (1980).
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation117(20), 2706–2715; discussion 2715 (2008).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet366(9496), 1545–1553 (2005).
   PubMed Web of Science ®Google Scholar
• A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA247(12), 1707–1714 (1982).
   PubMed Web of Science ®Google Scholar
• Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet357(9266), 1385–1390 (2001).
   PubMed Web of Science ®Google Scholar
• Tepper D. Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Congest. Heart Fail.5(4), 184–185 (1999).
   PubMedGoogle Scholar
• Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation106(17), 2194–2199 (2002).
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med.334(21), 1349–1355 (1996).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet362(9377), 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet353(9146), 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J.26(3), 215–225 (2005).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Weir MR, Shanifar S et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch. Intern. Med.163(13), 1555–1565 (2003).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359(9311), 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet358(9287), 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet355(9200), 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting – enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med.348(7), 583–592 (2003).
   PubMed Web of Science ®Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362(9386), 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet353(9169), 2008–2013 (1999).
   PubMed Web of Science ®Google Scholar
• Brunner M, Cooper-DeHoff RM, Gong Y et al. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study). Am. J. Cardiol.99(11), 1549–1554 (2007).
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Harris-Haywood S, Pressel S et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.168(2), 207–217 (2008).
   PubMedGoogle Scholar
• Economic costs of diabetes in the U.S. In 2007. Diabetes Care31(3), 596–615 (2008).
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342(3), 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106(25), 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Liu J, Grundy SM, Wang W et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am. Heart J.153(4), 552–558 (2007).
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. Arch. Intern. Med.168(9), 969–978 (2008).
   PubMed Web of Science ®Google Scholar
• Nigam A, Bourassa MG, Fortier A, Guertin MC, Tardif JC. The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. Am. Heart J.151(2), 514–521 (2006).
   PubMed Web of Science ®Google Scholar
• Garber AJ, Handelsman Y, Einhorn D et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr. Pract.14(7), 933–946 (2008).
   PubMedGoogle Scholar
• Bakris GL, Gaxiola E, Messerli FH et al. Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension44(5), 637–642 (2004).
   PubMed Web of Science ®Google Scholar
• Palmieri V, Bella JN, Arnett DK et al. Effect of Type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation103(1), 102–107 (2001).
   PubMed Web of Science ®Google Scholar
• Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care24(12), 2091–2096 (2001).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med.329(20), 1456–1462 (1993).
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet349(9069), 1857–1863 (1997).
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA288(19), 2421–2431 (2002).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens.21(5), 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Cooper-Dehoff RM. Cardiovascular therapies and risk for development of diabetes. J. Am. Coll. Cardiol.44(3), 509–512 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J. Am. Coll. Cardiol.53(5 Suppl.), S28–S34 (2009).
   Google Scholar
• Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet369(9557), 201–207 (2007).
   PubMed Web of Science ®Google Scholar
• Macfarlane DP, Paterson KR, Fisher M. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of Type 2 diabetes. Diabetes Obes. Metab.10(7), 533–544 (2008).
   PubMed Web of Science ®Google Scholar
• Henriksen EJ, Jacob S. Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes. Metab.5(4), 214–222 (2003).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens.20(9), 1879–1886 (2002).
   PubMed Web of Science ®Google Scholar
• Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med.351(20), 2058–2068 (2004).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Ostergren JB, Gerstein HC et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation112(1), 48–53 (2005).
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Renin-angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab.30(6), 487–496 (2004).
   PubMed Web of Science ®Google Scholar
• Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol.46(5), 821–826 (2005).
   PubMed Web of Science ®Google Scholar
• Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset Type 2 diabetes. Diabetes Care28(9), 2261–2266 (2005).
   PubMed Web of Science ®Google Scholar
• Opie LH, Schall R. Old antihypertensives and new diabetes. J. Hypertens.22(8), 1453–1458 (2004).
   PubMed Web of Science ®Google Scholar
• Bosch J, Yusuf S, Gerstein HC et al. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med.355(15), 1551–1562 (2006).
   PubMed Web of Science ®Google Scholar
• Califf RM, Boolell M, Haffner SM et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am. Heart J.156(4), 623–632 (2008).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Julius S, Mancia G et al. Effects of valsartan compared to amlodipine on preventing Type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J. Hypertens.24(7), 1405–1412 (2006).
   PubMed Web of Science ®Google Scholar
• Cooper-Dehoff R, Cohen JD, Bakris GL et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am. J. Cardiol.98(7), 890–894 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta AK, Dahlof B, Dobson J et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care31(5), 982–988 (2008).
   PubMed Web of Science ®Google Scholar
• Shafi T, Appel LJ, Miller ER, 3rd, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension52(6), 1022–1029 (2008).
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension48(2), 219–224 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplan NM, Carnegie A, Raskin P, Heller JA, Simmons M. Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia. N. Engl. J. Med.312(12), 746–749 (1985).
   PubMed Web of Science ®Google Scholar
• Helderman JH, Elahi D, Andersen DK et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes32(2), 106–111 (1983).
   PubMed Web of Science ®Google Scholar
• Murphy MB, Lewis PJ, Kohner E, Schumer B, Dollery CT. Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet2(8311), 1293–1295 (1982).
   PubMed Web of Science ®Google Scholar
• Cranston WI, Juel-Jensen BE, Semmence AM et al. Effects of Oral Diuretics on Raised Arterial Pressure. Lancet2(7315), 966–970 (1963).
   PubMed Web of Science ®Google Scholar
• Carter BL, Einhorn PT, Brands M et al. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension52(1), 30–36 (2008).
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Chrysant GS, Dimas B. Current and future status of beta-blockers in the treatment of hypertension. Clin. Cardiol.31(6), 249–252 (2008).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with b blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol.100(8), 1254–1262 (2007).
   PubMed Web of Science ®Google Scholar
• Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for Type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N. Engl. J. Med.342(13), 905–912 (2000).
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents? Am. J. Hypertens.11(10), 1258–1265 (1998).
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Wicklmayr M et al. Differential effect of chronic treatment with two β-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J. Hypertens.14(4), 489–494 (1996).
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Metra M, Charlesworth A et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart93(8), 968–973 (2007).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA292(18), 2227–2236 (2004).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J. Hypertens.21(8), 1563–1574 (2003).
   PubMed Web of Science ®Google Scholar
• Burke TA, Sturkenboom MC, Ohman-Strickland PA, Wentworth CE, Rhoads GG. The effect of antihypertensive drugs and drug combinations on the incidence of new-onset Type-2 diabetes mellitus. Pharmacoepidemiol. Drug Saf.16(9), 979–987 (2007).
   PubMed Web of Science ®Google Scholar
• Zidek W, Schrader J, Luders S et al. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. Cardiovasc Diabetol.7, 22 (2008).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Reboldi G, Gattobigio R. Is the development of diabetes with antihypertensive therapy a problem? – Pro. J. Clin. Hypertens. (Greenwich)8(2), 120–126 (2006).
   PubMedGoogle Scholar
• Moser M. Is new-onset diabetes of clinical significance in treated hypertensive patients? – Con. J. Clin. Hypertens. (Greenwich)8(2), 126–132 (2006).
   PubMedGoogle Scholar
• Almgren T, Wilhelmsen L, Samuelsson O et al. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J. Hypertens.25(6), 1311–1317 (2007).
   PubMed Web of Science ®Google Scholar
• Samuelsson O, Pennert K, Andersson O et al. Diabetes mellitus and raised serum triglyceride concentration in treated hypertension – are they of prognostic importance? Observational study. BMJ313(7058), 660–663 (1996).
   PubMed Web of Science ®Google Scholar
• Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension33(5), 1130–1134 (1999).
   PubMed Web of Science ®Google Scholar
• Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ326(7391), 681 (2003).
   PubMed Web of Science ®Google Scholar
• Eberly LE, Cohen JD, Prineas R, Yang L. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care26(3), 848–854 (2003).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension43(5), 963–969 (2004).
   PubMed Web of Science ®Google Scholar
• Kostis JB, Wilson AC, Freudenberger RS et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am. J. Cardiol.95(1), 29–35 (2005).
   PubMed Web of Science ®Google Scholar
• Barzilay JI, Davis BR, Cutler JA et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med.166(20), 2191–2201 (2006).
   PubMed Web of Science ®Google Scholar
• Aksnes TA, Kjeldsen SE, Rostrup M et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension50(3), 467–473 (2007).
   PubMed Web of Science ®Google Scholar
• Alderman MH. New onset diabetes during antihypertensive therapy. Am J. Hypertens.21(5), 493–499 (2008).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment, and outcome. Hypertension50(3), 459–460 (2007).
   PubMed Web of Science ®Google Scholar
• Aksnes TA, Kjeldsen SE, Rostrup M et al. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. J. Hum. Hypertens.22(8), 520–527 (2008).
   PubMed Web of Science ®Google Scholar
• Preiss D, Zetterstrand S, McMurray JJ et al. Predictors of Development of Diabetes in Patients with Chronic Heart Failure in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care (2009).
   PubMedGoogle Scholar
• Rajala U, Qiao Q, Laakso M, Keinanen-Kiukaanniemi S. Antihypertensive drugs as predictors of Type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Res. Clin. Prac.50(3), 231–239 (2000).
   PubMed Web of Science ®Google Scholar
• American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr. Pract.12(2), 193–222 (2006).
   PubMedGoogle Scholar
• Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J. Renin Angiotensin Aldosterone Syst.7(2), 61–63 (2006).
   PubMed Web of Science ®Google Scholar